Isoliquiritigenin

SKU: orb1310346

Description

Isoliquiritigenin is a bioactive flavonoid with antiviral activity against influenza (EC50=24.7 µM) and potent aldose reductase inhibition (IC50=320 nM). It also exhibits antitumor properties, making it a compound of interest for research in virology, diabetes complications, and oncology, supported by both in vitro and in vivo studies.

Research Area

Cell Biology, Infectious Disease & Virology, Metabolism Research

Key Properties

• CAS Number: 961-29-5
• MW: 256.253
• Purity: 99.44% (May vary between batches)
• Formula: C₁₅H₁₂O₄
• SMILES: O=C(C1=CC=C(O)C=C1O)/C=C/C2=CC=C(O)C=C2
• Target: Autophagy,Influenza Virus,Reductase,Apoptosis
• Solubility: DMSO:62.3 mg/mL (243.12 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5.1 mg/mL (19.9 mM);Ethanol:22 mg/mL (85.85 mM)

Bioactivity

• Target IC50:
  HUVECs:41.17 μM|LO2 cells:> 60 µM|C2C12 cells:26.34 μg/mL|influenza virus:24.7 μM (EC50)|Aldose reductase:320 nM|SiHa cells:53.8 μM|Hep b3B cells:42.84 ± 2.01 µM|HepG2 cells:27.71 μM|HeLa cells:58.1 μM|A549 cells:> 20 μM|C-33-A cells:32.83 μM|SK-MEL-28 cells:75 μM|U-373MG cells:68 μM|HEK293T cells:3.42 μg/mL|3T3-L1 cells:96.4 μM
  Read more...
• In Vivo:
  METHODS: To assay anti-tumor activity in vivo, Isoliquiritigenin (50 mg/kg) was injected intraperitoneally into BALB/c-nu/nu mice bearing Hep3B xenografts once daily for three weeks. RESULTS: Isoliquiritigenin-treated mice had reduced tumor burden in terms of mean tumor size or xenograft weight.
  Read more...
• In Vitro:
  METHODS: Normal human hepatocyte cell line LO2 and HCC cell line Hep3B were treated with Isoliquiritigenin (30-60 µM) for 24-72 h. Cell viability was measured by MTT assay. RESULTS: Isoliquiritigenin showed significant cytotoxicity against Hep3B cells with an IC50 of 42.84±2.01 µM at 48 h. This effect was concentration and time dependent. However, at the same Isoliquiritigenin stimulation intensity, the survival of LO2 cells was significantly less affected with an IC50 >60 µM. METHODS: Human colorectal cancer cells HCT-116 were treated with Isoliquiritigenin (20 µM) for 24 h. Apoptosis was detected by Flow cytometry. RESULTS: Treatment of HCT-116 cells with Isoliquiritigenin resulted in a significant increase in apoptosis (17.26%) in the treated group compared to the NC group (7.37%).
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Aldose reductase, Aldose Reductase, Autophagy, Apoptosis, ISL, InfluenzaVirus, Influenza Virus, Isoliquiritigen, Isoliquiritigenin, GU 17, GU17, GU-17, SJ 000286237, SJ-000286237, SJ000286237

Compound Identifiers

PubChem CID

638278